tetano
Editor, Senior Moderator
Int Immunopharmacol
. 2026 Apr 30:181:116753.
doi: 10.1016/j.intimp.2026.116753. Online ahead of print.
Fe[SUB]2[/SUB]O[SUB]3[/SUB]-based nanozyme synergistic with oseltamivir for broad-spectrum inhibition of influenza A virus
Yongkang Li[SUP] 1 [/SUP], Yuqing Jiang[SUP] 2 [/SUP], Yun Zhang[SUP] 3 [/SUP], Yu Sun[SUP] 1 [/SUP], Chong Zhang[SUP] 1 [/SUP], Yexing Wang[SUP] 1 [/SUP], Yuanguo Li[SUP] 4 [/SUP], Nan Li[SUP] 4 [/SUP], Zuobin Wang[SUP] 5 [/SUP], Butian Zhang[SUP] 6 [/SUP], Weiyang Sun[SUP] 7 [/SUP], Xiuxia He[SUP] 8 [/SUP]
Affiliations
Influenza A virus infection is responsible for seasonal epidemics worldwide, which have a significant impact on public health and economic development. The therapeutic efficacy of the widely used antiviral drug oseltamivir (OTV) is often compromised by the emergence of drug resistance and adverse drug reactions in the body. The advantageous properties of γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB] nanoparticles, which include abundant surface hydroxyl groups, excellent biocompatibility, and nanoenzymatic activity, make them promising candidates for use as drug delivery platforms. In this study, γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB] was conjugated to OTV via Fe-O-P coordination bonding to construct a γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV nanodrug, with the aim of enhancing antiviral efficacy through combination therapy, reducing the required dose of OTV, and thereby potentially delaying the emergence of drug resistance. γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV exhibited significant inhibitory activity against influenza virus infection in both in vitro and in vivo models. γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV directly disrupts the viral envelope structure to inactivate the virus and suppress neuraminidase activity, inhibiting the release of viral progeny. In addition, γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV demonstrated effective scavenging of intracellular reactive oxygen species, thereby alleviating oxidative stress-induced inflammation and suppressing the cytokine. Significantly, γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV is a broad-spectrum inhibitor against different subtypes of influenza A viruses. This study presents a novel strategy for the application of nanomaterials in antiviral therapeutics.
Keywords: Anti-influenza virus agent; Broad-spectrum inhibition; Combined therapy; Oseltamivir; γ-Fe(2)O(3).
. 2026 Apr 30:181:116753.
doi: 10.1016/j.intimp.2026.116753. Online ahead of print.
Fe[SUB]2[/SUB]O[SUB]3[/SUB]-based nanozyme synergistic with oseltamivir for broad-spectrum inhibition of influenza A virus
Yongkang Li[SUP] 1 [/SUP], Yuqing Jiang[SUP] 2 [/SUP], Yun Zhang[SUP] 3 [/SUP], Yu Sun[SUP] 1 [/SUP], Chong Zhang[SUP] 1 [/SUP], Yexing Wang[SUP] 1 [/SUP], Yuanguo Li[SUP] 4 [/SUP], Nan Li[SUP] 4 [/SUP], Zuobin Wang[SUP] 5 [/SUP], Butian Zhang[SUP] 6 [/SUP], Weiyang Sun[SUP] 7 [/SUP], Xiuxia He[SUP] 8 [/SUP]
Affiliations
- PMID: 42066550
- DOI: 10.1016/j.intimp.2026.116753
Influenza A virus infection is responsible for seasonal epidemics worldwide, which have a significant impact on public health and economic development. The therapeutic efficacy of the widely used antiviral drug oseltamivir (OTV) is often compromised by the emergence of drug resistance and adverse drug reactions in the body. The advantageous properties of γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB] nanoparticles, which include abundant surface hydroxyl groups, excellent biocompatibility, and nanoenzymatic activity, make them promising candidates for use as drug delivery platforms. In this study, γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB] was conjugated to OTV via Fe-O-P coordination bonding to construct a γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV nanodrug, with the aim of enhancing antiviral efficacy through combination therapy, reducing the required dose of OTV, and thereby potentially delaying the emergence of drug resistance. γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV exhibited significant inhibitory activity against influenza virus infection in both in vitro and in vivo models. γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV directly disrupts the viral envelope structure to inactivate the virus and suppress neuraminidase activity, inhibiting the release of viral progeny. In addition, γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV demonstrated effective scavenging of intracellular reactive oxygen species, thereby alleviating oxidative stress-induced inflammation and suppressing the cytokine. Significantly, γ-Fe[SUB]2[/SUB]O[SUB]3[/SUB]-OTV is a broad-spectrum inhibitor against different subtypes of influenza A viruses. This study presents a novel strategy for the application of nanomaterials in antiviral therapeutics.
Keywords: Anti-influenza virus agent; Broad-spectrum inhibition; Combined therapy; Oseltamivir; γ-Fe(2)O(3).